全文获取类型
收费全文 | 84篇 |
免费 | 57篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 17篇 |
妇产科学 | 1篇 |
基础医学 | 1篇 |
临床医学 | 14篇 |
内科学 | 29篇 |
皮肤病学 | 5篇 |
神经病学 | 9篇 |
外科学 | 15篇 |
预防医学 | 7篇 |
肿瘤学 | 36篇 |
出版年
2024年 | 1篇 |
2023年 | 7篇 |
2022年 | 1篇 |
2021年 | 7篇 |
2020年 | 10篇 |
2019年 | 6篇 |
2018年 | 15篇 |
2017年 | 11篇 |
2016年 | 16篇 |
2015年 | 12篇 |
2014年 | 17篇 |
2013年 | 7篇 |
2012年 | 6篇 |
2010年 | 13篇 |
2009年 | 4篇 |
2008年 | 2篇 |
2007年 | 2篇 |
2006年 | 1篇 |
2005年 | 1篇 |
2003年 | 2篇 |
排序方式: 共有141条查询结果,搜索用时 15 毫秒
31.
32.
Greg Dueck MD Neil Chua MD Angeli Prasad CCRP Daygen Finch MD Doug Stewart MD Darrell White MD Richard van der Jagt MD James Johnston MD Andrew Belch MD Tony Reiman MD 《Cancer》2010,116(19):4541-4548
BACKGROUND:
Novel therapies are needed to improve outcomes in T‐cell lymphomas. The authors report the interim results of a prospective multicenter trial evaluating lenalidomide in T‐cell lymphomas.METHODS:
Patients with recurrent and refractory T‐cell lymphomas other than mycosis fungoides and untreated patients ineligible for combination chemotherapy were prescribed oral lenalidomide (25 mg daily) on Days 1 to 21 of each 28‐day cycle until disease progression, death, or unacceptable toxicity. The primary endpoint was overall response rate. Secondary endpoints were progression‐free survival (PFS), overall survival (OS), and safety. The 2‐stage design allows for up to 40 patients.RESULTS:
At the time of this interim analysis, 24 patients were enrolled in this study, and 23 were evaluable for response. The median age was 65 years. The overall response rate was 7 (30%) of 23; all were partial responses. Two patients had stable disease for ≥5 cycles. Responses were seen in anaplastic, angioimmunoblastic, and peripheral T‐cell unspecified histologies. Median PFS was 96 days (range, 8‐696+ days). Median OS was 241 days (range, 8‐696+ days). The most common grade 4 adverse event was thrombocytopenia (33%). The most common grade 3 adverse events were neutropenia (21%), febrile neutropenia (17%), and pain not otherwise specified (17%). Rash correlated with response to therapy (P = .003).CONCLUSIONS:
In patients with recurrent and refractory T‐cell lymphomas, oral lenalidomide monotherapy has clinical activity, and toxicity is consistent with the known safety profile of lenalidomide. Further study of lenalidomide in these diseases is warranted. Cancer 2010. © 2010 American Cancer Society. 相似文献33.
Longitudinal improvement and stability of olfactory function in the evaluation of surgical management for chronic rhinosinusitis 下载免费PDF全文
34.
35.
Weight change during childhood acute lymphoblastic leukemia induction therapy predicts obesity: A report from the Children's Oncology Group 下载免费PDF全文
36.
37.
38.
39.